These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 7112499)

  • 1. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs.
    Thomas DP; Merton RE; Barrowcliffe TW
    Ann N Y Acad Sci; 1989; 556():313-22. PubMed ID: 2735662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities.
    Bara L; Trillou M; Mardiguian J; Samama M
    Nouv Rev Fr Hematol (1978); 1986; 28(6):355-8. PubMed ID: 3562219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies in man and experimental animals of a low molecular weight heparin fraction.
    Thomas DP; Merton RE; Lewis WE; Barrowcliffe TW
    Thromb Haemost; 1981 Jun; 45(3):214-8. PubMed ID: 7281101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
    Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of continuous low-dose intravenous heparin administered during operation on postoperative measurements of antithrombin III and antifactor Xa.
    Jennings SA; Heather BP; Greenhalgh RM
    Surgery; 1984 Sep; 96(3):550-5. PubMed ID: 6474360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions.
    Hoppensteadt DA; Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):112-20. PubMed ID: 3898369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
    Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
    Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model.
    Thomas DP; Merton RE; Gray E; Barrowcliffe TW
    Thromb Haemost; 1989 Apr; 61(2):204-7. PubMed ID: 2546282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
    Diness V; Ostergaard PB
    Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats.
    Hobbelen PM; van Dinther TG; Vogel GM; van Boeckel CA; Moelker HC; Meuleman DG
    Thromb Haemost; 1990 Apr; 63(2):265-70. PubMed ID: 2363127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
    Walenga JM; Petitou M; Lormeau JC; Samama M; Fareed J; Choay J
    Thromb Res; 1987 Apr; 46(2):187-98. PubMed ID: 3603420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.